| Study coordinator Name - Ashley Walker, DVM Email - alwalker@ucdavis.edu Phone - (530) 752-1393 |
| Animal: | Cats |
| Age: | 1-12 years |
| Sex: |
Any
|
| Healthy Pets: | No |
| Keywords: | cat, hcm, cardiomyopathy, subclinical, hypertrophic cardiomyopathy |
| Type: | Clinical Drug Trial |
Rapamycin has been shown to reverse HCM in rodents and in people – this study will be the first study to evaluate its potential in cats. A small study was conducted in healthy cats to evaluate the drug effects and safety before starting this clinical trial.
This is a six month clinical trial and consists of four visits in-person, at enrollment, 2 months, 4 months, and six months. The is a drug trial and cats will receive either the study drug (rapamycin) or placebo once weekly by mouth for the entire six months.
Pet owners will be responsible for bringing their cat in for each scheduled visit (minimum of four) and administration of the once weekly medication for the six month period.
Eligible: Cats with HCM that are otherwise healthy. Must be <12 yrs of age and weigh 7.7lbs or more.
Ineligible: Cats with congestive heart failure, hypertension, chronic kidney disease, anemia or other serious illness requiring ongoing medication that alters cardiac function.
To determine eligibility, we will need:
- Cardiology exam
- Echocardiogram
- Chest X-rays
- Bloodwork
- Blood pressure measurement
- Electrocardiogram
Cats enrolled on the study will be under the care of a board-certified cardiologist .
Rapamycin or placebo tablets will be provided for the 6-month treatment period.
Hospital costs up to $1000 if the cat experiences an adverse event or events as a result of taking part in the study and needs medical treatment.
Trial sponsored by TriviumVet
| Location |
Davis, CA 95616
- hypertrophic cardiomyopathy
- HCM
- Cat
- cardiac
- disease
- heart
Have any questions or want to learn more? Leave your contact details below and the research team will reach out to you.